| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0149-2918(01)80103-X |
| P698 | PubMed publication ID | 11558860 |
| P50 | author | Jerome J. Schentag | Q125760346 |
| P2093 | author name string | Smith PF | |
| Forrest A | |||
| Ballow CH | |||
| Booker BM | |||
| P2860 | cites work | Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model | Q43617611 |
| Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae | Q43627840 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. | Q52374966 | ||
| Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis. | Q52430183 | ||
| Some suggestions for measuring predictive performance | Q52875851 | ||
| Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. | Q54344376 | ||
| A Bayesian extension of the minimum AIC procedure of autoregressive model fitting | Q61440894 | ||
| Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis | Q74250668 | ||
| Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria | Q33976467 | ||
| Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 | ||
| Role of pharmacokinetics in the outcome of infections | Q39639407 | ||
| Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins | Q40431109 | ||
| Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia | Q40820075 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials | Q42671287 | ||
| Effect of dose and schedule on cefoperazone pharmacodynamics in an in Vitro model of infection in a neutropenic host | Q43476071 | ||
| P433 | issue | 8 | |
| P921 | main subject | pharmacodynamics | Q725307 |
| hospitalization | Q3140971 | ||
| pharmacokinetics | Q323936 | ||
| aztreonam | Q418546 | ||
| P304 | page(s) | 1231-1244 | |
| P577 | publication date | 2001-08-01 | |
| P1433 | published in | Clinical Therapeutics | Q15716601 |
| P1476 | title | Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients | |
| P478 | volume | 23 |
| Q38873850 | A review of the pharmacokinetics and pharmacodynamics of aztreonam |
| Q79100822 | AUIC in Humans: A Fact-Based Discussion |
| Q93085292 | Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients |
| Q64129066 | Aminoglycoside Dosing in Obesity |
| Q33769931 | Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi |
| Q35623055 | Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid |
| Q37942767 | Comparison of mortality between nosocomial and community-acquired febrile neutropenia patients treated initially with cefazolin plus tobramycin: retrospective chart review |
| Q40573594 | Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis |
| Q35547236 | Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials |
| Q42952777 | Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered |
| Q53070940 | Individualising Therapy to Minimize Bacterial Multidrug Resistance. |
| Q36162355 | Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents |
| Q44104691 | Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing |
| Q36094883 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation |
| Q37956403 | Pharmacological considerations for the proper clinical use of aminoglycosides |
| Q39071799 | Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. |
| Q57789728 | Simplified Aztreonam Dosing in Patients with End-Stage Renal Disease: Results of a Monte Carlo Simulation |
| Q45170003 | The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe |
| Q37980230 | Tobramycin for the treatment of bacterial pneumonia in children |
Search more.